`
`Can Stemtt [ Shield Therapeutics
`
`§SHIELD
`
`IHIIAPIUIIID Hr
`
`Peeple
`
`Our achflrensants would not he possibie -i--.-itho_it the outs-tariding team that make up
`
`Shield Therapeutics staff management and board of directors.
`
`CHIEF EXECUTIVE OFFICER AND CO-FOUHDER
`
`Carl Sterritt
`
`With approximately 20 years’ of management and executive level experience in pharmaceutical development
`
`and commercialisation in both large and small company settings. Carl has led the Company as its CEO since
`
`he co-founded the Group in 2008 together with Dr.Christian Schweiger.
`
`Previously. Carl held senior management roles at United Therapeutics and Encysive Pharmaceuticals. working
`
`on innovative therapies for the treatment of pulmonary arterial hypertension. Carl joined United
`
`Therapeutics to establish the company's European operations in preparation for the marketing approval of
`
`Remodulin®. running the subsidiary for six years. In collaboration with physicians in Germany. he was
`
`responsible for and holds patents related to United Therapeutics' decision to develop and commerciali
`
`treprostinil: now successfully commercialised in the US as Tyvaso‘”. Carl was instrumental in the success. ....
`
`commercial launch of Thelini“ and the rapid growth of Encysive's European operations. Carl founded the
`
`Group after Encysive was acquired by Pfizer lnc. for more than $500M
`
`BACK TO TEAM
`
`httpsuFMwwehleldflterapeuflcs.oorm‘leanvceri'eterrlw
`
`H3
`
`UNITED THERAPEUTICS, EX. 2025
`WATSON LABORATORIES V. UNITED THERAPEUTICS. lPR2017-01622
`Page 1 of 1
`
`